Vaccine hesitancy is increasing cases of a once eliminated disease in the U.S., putting plan sponsors in a unique position to educate and engage their members.

Programs designed to build awareness and address social needs are key to improving health equity.

Breaking down what plan sponsors should know about HAE, its challenges and therapies.

By supporting and encouraging evidence-based access to gene therapy, payers and other segments of U.S. society will be positioned to benefit from future advancements and biopharmaceutical breakthroughs that drive systemic change.